Review Article

Immune System Acts on Orthodontic Tooth Movement: Cellular and Molecular Mechanisms

Yajun Gao,1 Qingqing Min,1 Xingjia Li,2 Linxiang Liu,3 Yangyang Lv,1 Wenjie Xu,1 Xudong Liu,4 and Hua Wang4

1Department of Endodontics, Wuxi Stomatology Hospital, Wuxi, China
2Department of Prosthodontics, Wuxi Stomatology Hospital, Wuxi, China
3Department of Implantology, Wuxi Stomatology Hospital, Wuxi, China
4Wuhu Stomatology Hospital, Wuhu, China

Correspondence should be addressed to Hua Wang; 1172996659@qq.com

Received 14 July 2022; Revised 5 September 2022; Accepted 29 September 2022; Published 25 October 2022

Academic Editor: Rafael Scaf De Molon

Copyright © 2022 Yajun Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Orthodontic tooth movement (OTM) is a tissue remodeling process based on orthodontic force loading. Compressed periodontal tissues have a complicated aseptic inflammatory cascade, which are considered the initial factor of alveolar bone remodeling. Since skeletal and immune systems shared a wide variety of molecules, osteoimmunology has been generally accepted as an interdisciplinary field to investigate their interactions. Unsurprisingly, OTM is considered a good mirror of osteoimmunology since it involves immune reaction and bone remodeling. In fact, besides bone remodeling, OTM involves cementum resorption, soft tissue remodeling, orthodontic pain, and relapse, all correlated with immune cells and/or immunologically active substance. The aim of this paper is to review the interaction of immune system with orthodontic tooth movement, which helps gain insights into mechanisms of OTM and search novel method to short treatment period and control complications.

1. Introduction

Orthodontic tooth movement (OTM) is a complicate remodeling of biological tissue in dentoalveolar complex. Classic “pressure-tension” theory proposes that mechanical force is capable of compressing periodontal ligament (PDL) and reducing blood flow on the compression side [1]. Cytokine secretion and oxygen tension decreasing lead to temporary sterile inflammation [2], followed by a wide variety of immune cells activation. The activated immune cells (e.g., T cell) have been found to play a crucial role in orthodontic treatment [3–5]. The immune–bone interaction has been confirmed in different systemic diseases [6, 7]. Jiang et al. reviewed the effect of immune-related cytokines on orthodontic bone remodeling [8], whereas they focused on regulation of osteoclast/osteoblast. In fact, OTM has been reported as a more complicated process than pure bone remodeling. This review places a focus on other aspects in OTM concerned by orthodontists and patients (e.g., cementum resorption, soft tissue remodeling, orthodontic pain, treatment for patients with diabetes, and orthodontic relapse). The multidimensional illustration of role of immune in OTM takes on a critical significance to understand underlying mechanisms and optimize clinical strategies.

2. Alveolar Bone Remodeling

PDL is a fibrous structure connecting the cementum on the tooth root surface to the alveolar bone and fix the tooth in the alveolar socket [9], which makes tooth movement possible. PDL is compressible to attenuate the occlusal stresses. When tooth subjects lateral force, it moves slightly along the direction of force, and the actions of PDL are different on the compression side and the tension side. On the compression side, the vessels are squeezed and local ischaemia ensues [10]. Moreover, oxygen tension changing incites an increased anaerobic respiration in periodontal cells (e.g.,
fibroblasts). Chemical microenvironment alteration contributes to the production of mediators (e.g., prostaglandins), while adjusting the balance between osteoclast and osteoblast to enhance bone remodeling. Osteoclast differentiation is facilitated, thus resulting in alveolar bone resorption on the compression side. In contrast, the PDL fiber is stretched on the tension side, meanwhile, osteoblast activity increases and bone trabecula forms along direction of force applied. Besides, cementum covered tooth root is less susceptible to stress, thus revealing that tooth root will not remodel like alveolar bone, which is the biological basement for orthodontic tooth movement. Ultimately, intact tooth moves in alveolar bone to relieve the compression of PDL.

2.1. Osteoclasts. Osteoclast is one of the critical bone cell populations. Figure 1 presents the role and interaction of osteoclasts with immune system in OTM. Osteoclasts and ostal macrophages competitively differentiate from myeloid progenitor. The myeloid progenitor can differentiate into osteoclasts in the presence of macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), whereas it turns into mono macrophage under the stimulus of M-CSF alone [11]. Moreover, it has been confirmed that macrophage can affect osteoclast formation and activation [12]. First, activation of macrophage leads to low pH and local bone demineralization to construct attachment site for osteoclast [13]. Second, macrophage is highly heterogeneous, which refers to different functional phenotypes it exhibits in response to local changes in the microenvironment, such as alteration of cytokines, pH-value, and metabolite even oxygen concentrations [14]. For the sake of understanding and discussion, it is generally categorized into M1, proinflammatory, classically activated macrophages associated to initial inflammation, and M2 anti-inflammatory, alternatively activated macrophages which limits inflammation and tissue injury. It is noticeable that macrophage polarization states are much more complex, and M2 macrophages can be further subdivided in M2a, M2b, M2c, and M2d. However, roles of these subtypes in osteoimmunology remain unclear, so below discussion is still based on classic categorization. M1 macrophages secrete TNF-α and IL-1β to induce osteoclastogenesis, while IL-4 and IL-10 released by M2 macrophages suppress osteoclastogenesis by inhibiting NFATc1 [12], thus revealing that myeloid lineage cells adjust its own differentiation direction by changing external inflammatory environments. On the other hand, the polarization states of macrophage are consecutively and interconvertible, so the influences of macrophages on osteoclast are not fixed.

The interaction between innate immune and osteoclast takes on a critical significance during OTM. To facilitate osteoclast formation, M1/M2 macrophage ratio is increased to exert a more significant proinflammatory effect [15, 16]. The enhancement can be achieved by TH1 cytokines [17, 18] and NLRP3 inflammasome from periodontal ligament cell (PDLC) [19]. Moreover, autophagy of periodontal ligament stem cells (PDLSC), a kind of stem cell with multilineage differentiation potential in periodontal ligament, can promote M1 polarization via inhibiting the AKT signaling pathway as well [20]. Besides, orthodontic mechanical force affects innate immune cell by directly acting on macrophages. The macrophages subjected to compressive force express cytokines rapidly after the application of force (e.g., MMP-8, TNF-α, IL-6, PGE-2, and VEGF) [21]. The above cytokines facilitate immune cell recruitment, vessel growth to aggregate inflammation, thus accelerating osteoclast differentiation and tooth movement [22–25]. Notably, oxygen plays a certain role in this regulation of macrophages since TNF is inhibited partly by increased oxygen [26]. Thus, hypoxia-associated protein (e.g., hypoxia-inducible factor-1 (HIF-1)) can be the target for modulating macrophages to optimize orthodontic treatment. Complement is another essential part of innate immunity, which has been considered to affect bone homeostasis [27]. Ignatius et al. suggested that osteoblasts and osteoclasts are capable of activating complement by cleaving complement component 5 (C5) to its active form C5a. Furthermore, C3a and C5a induce osteoclast formation even in the absence of RANKL and M-CSF [28]. The above findings reveal that complement is capable of modulating osteoclast formation independently.

RANKL/RANK/OPG system has been confirmed as the critical pathway for osteoblast to regulate osteoclast. RANKL, one of the TNF family members, binds to RANK, a receptor expresses on osteoclast progenitor cells, to
mature osteoclast [29]. By binding to RANKL and blocking it, OPG is a decoy receptor that plays a certain role in the prevention of extra bone resorption as a bone protective factor [30]. Skeletal system achieves bone homeostasis by maintaining dynamic balance between bone resorption and deposition via RANKL/RANK/OPG pathway. In orthodontic treatment, it has been found that orthodontic force increases the concentration of RANKL in gingival crevicular fluid, thus activating osteoclasts and increasing the amount of experimental tooth movement in rats [31, 32]. In contrast, the overexpression of OPG in rat periodontium inhibits bone remodeling and OTM [33]. However, RANKL/RANK/OPG system is easy to intervene because they are expressed not only in osteoblast. Entire B cell lineage including B cell precursors, immature B cells, and plasma cells account for about 64% of total OPG production. Meanwhile, B cell also expresses RANKL that leads to bone loss. Both increase as aging but OPG cannot fully compensate for endogenous RANKL for the elders [34, 35]. When RANKL gene is deleted from B cells in mice, bone loss arising from ovariec- tomy is partially reversed [36]. The above research has indicated that B cell can be a potential target to reverse bone resorption resulted from age-associated OPG-RANKL imbalance. Moreover, systemic immune system diseases affect bone metabolism by modulating B cells. The flow cytometry results have suggested that HIV-infected individuals received B cell dysmaturity, thus con- tributing to decreased bone mass and OPG, as well as osteoporosis [37]. Meanwhile, B cell is considered a source of RANKL to facilitate osteoclastogenesis in periodontitis. The above evidence suggests that B cells can activate osteoclasts by regulating RANKL and OPG levels, and they influence periodontium. However, the direct evidence supporting that B cells directly modulate bone remodeling induced by orthodontic force is scanty. The similar situation pertains to the T cell, another type of important immune cell capable of regulating bone homeostasis. T cells induce B cells by expressing CD40 ligand which binds to CD40 on the B cell surface to release OPG [38]. Li et al. [38] observed that T-cell-deficient nude mice express lower level of B cell-derived OPG. Interestingly, activated T cells can initiate bone destruction by releasing TNF-α in inflammation and under pathological conditions (e.g., estrogen deficiency) [39]. It is also capable of secreting IFN-γ which polarize macrophages into M1 [40, 41] and releasing RANKL which induces osteoclasts differentiation by binding to RANK [42, 43]. Furthermore, inhibition of T cell-derived RANKL by microRNA-21 leads to OTM retard in mice [4], thus revealing that the T cell affects osteoclast activity in orthodontic treatment, which can explain why T cell is required for OTM [3]. Besides directly regulating cells, immune system also interacts with foreign microorganisms to affect bone homeo- stasis. Recent reports showed that probiotics have impacts on immune system and bone [44–47]. It is widely accepted that probiotics can maintain bones by reducing inflamma- tory factors. In particular, Sjögren et al. found that CD4+ T cells along with TNF-α and IL-6 they secreted decline in bone marrow, serum, and spleen in Germ-free mice, thus indicating the decrease of osteoclastogenesis and the increase of bone mass in absence of intestinal flora [48]. Despite oral cavity is a part of digestive system harboring the second most abundant microbiota after the gastrointestinal tract [49], the interaction between probiotics and oral flora is still ambiguous compared to intestinal flora. On the other hand, some study have reported that oral supplemen- tation of Bacillus subtilis reduces alveolar bone loss in rats with periodontitis [50] and decreases alveolar remodeling in OTM [51], even though underlying mechanism remains unknown. Anyway, more investigations are necessary, and it is expected that probiotic therapy can be clinically used in periodontal or orthodontic treatment in the future.

Hormone has been widely known as an essential regulator of immune system, some of which significantly affect osteoclasts. For instance, adrenal glucocorticoid (GC) is a common inhibitor of immune system since it can suppress cytokine secretion and induce immune cells death [52]. In vivo experiment results have suggested that GC restrains osteoclast activity via GC receptor [53]. Prostaglandin E2 (PGE2) is another widely known homeostatic factor dominating in late/chronic stages of immunity [54]. PGE2 can be synthesized by osteoblastic cell lineage and stimulate osteoclast formation and differentiation [55, 56]. However, some reports about hormones effect have been contradic- tory. Kaji et al. suggested that dexamethasone enhances osteoclast-like cell formation [57], and Take et al. observed inhibition of human osteoclasts by PGE2 in vitro [58]. The above findings were achieved probably because hormone target cells are so wide range that some of them modulate osteoclast via other pathways. Another important bone homeostasis-associated hormone is estrogen. Postmenopausal women with deficient serum levels of estrogen face a higher risk of osteoporosis [59]. Moreover, ovariec- tomy-induced mice are considered the most common osteoporosis animal model. Since estrogen significantly prevents osteo- clast formation and differentiation while increasing apo- ptosis by binding to receptors [60], recent research has suggested that mitochondrial deacetylase sirtuin-3 (Sirt3) plays a certain role in the estrogen deficient-induced bone resorption [61]. In addition, a considerable number of types of immune cells express estrogen receptors (e.g., TH1, TH2, mast cell, basophilic cell, B cell, dendritic cell, macrophage, and native CD4+ T cell) [62]. Uehara et al. suggested that immune cells play a role of mediator to bridge estrogen and osteocytes and reviewed possible pathways [63]. Parathyroid hormone (PTH) is an 84-amino-acid peptide hormone with great application potential in bone healing. PTH increases the RANKL/OPG ratio to exert osteoclast indirectly [64]. In the bone, PTH increases TNF production [65] and activates T cells expressing CD40L directly [66], positively correlated with osteoclast activity. However, it also has proosteogenic activity since intermittent treatment with PTH analogs is approved as bone anabolic osteoporosis treatment strategy. Anyway, the above evidence emerges that there is interaction of immune cells and osteoclasts.

The major origin of osteoclasts responsible for bone resorption during orthodontic treatment has been found as
preosteoclasts recruited from bone marrow [67, 68]. Interestingly, recent studies have reported that some mature immune cells of monocyte lineage can also differentiate into osteoclast under specific stimulation. Dendritic cells (DCs), the most potent antigen-presenting cells, have been found to be transdifferentiated into active osteoclast in the presence of RANKL and M-CSF [69]. Even mpeg1-positive macrophages can be recruited by Cxcl9l from osteoblast progenitors to bone matrix and differentiate into osteoclasts [70]. Moreover, recruitment of osteoclast is correlated with numerous immune cells and cytokines. T cell secretes IFN-γ, RANKL, and IL-17A to induce inflammation-promoting osteoclast commitment and bone loss [34]. Furthermore, Wald et al. confirmed that osteoclasts, monocytes, and neutrophils are recruited by γδ T cells in mice during OTM [71] (Figure 2).

2.2. Osteoblast. Osteoblasts refer to bone-building cells derived from the mesenchymal/mesodermal lineage, which have been identified in tension side of tooth in OTM [72]. During OTM, Cbfα1 and Runx2 have been found as the earliest two transcriptional factors initiating bone formation [29]. In addition, other proteins have been considered as osteogenesis markers, including alpha-smooth muscle actin (α-SMA), osteopontin (OPN), osteocalcin (OC), bone morphogenetic proteins (BMPs), transforming growth factor-beta (TGF-β), Indian hedgehog, and ostrix [29, 73]. Since the term “osteimmune” was coined firstly in a publication which described regulation of osteoclastogenesis by T cells [74], the interaction between osteoblast and immune system gradually emerges. The osteoblast-osteoclast coupling is widely accepted, and RANKL/RANK/OPG system referred in the last sections is the most important coupling pathway between them. Moreover, osteoclasts can enhance osteoblast differentiation by expressing membrane-bound ephrinB2 that binds the EphB4 receptor on osteoclast progenitors [75], but osteoblast activation precedes commitment of osteoclasts [73]. As osteoclasts resorb bone matrix, factors from the matrix are released to regulate osteoblast activity, which consist of TGF-β and insulin-like growth factors (IGFs) [76]. It was reported that some coupling mechanisms between osteoblasts and osteoclasts are involved in immunoregulation. For instance, osteoblast lineage releases M-CSF [77], vascular endothelial growth (VEGF) [78], and nitric oxide [79] necessary for programming of osteoclast formation, which all can interfere immune microenvironment.

In addition, osteoblast directly initiates inflammation under certain conditions. IL-1β, C3a, and C5a promote the release of IL-6 and IL-8 in osteoblast [28]. LPS induces osteoblasts to express proinflammatory cytokines through mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) signaling pathway [80]. Besides, osteoblasts are the responsive cells for proinflammatory cytokines (e.g., IL-1, IL-11, oncostatin-M, leukemia inhibitory factor, and TNF-α). However, numerous studies have suggested that inflammation has a negative effect on bone forming. For instance, IL-1β inhibits human osteoblast migration and differentiation [81]. TNF-α downregulates Runx2 expression and induces apoptosis in osteoblasts [76]. The above findings have revealed that osteoblast contributes to local inflammation, thus inhibiting osteogenesis from the formation of a self-negative feedback regulatory mechanism. However, effect of immune response is not always negative for osteogenesis. It is reported that osteoclast-derived C3a induces osteoclast differentiation [82], although Ignatius et al. had negative results in another similar in vitro research employing C3a and C5a [28]. Thus, further investigation is needed.

B cells also interact with osteoblast. B cell is a key regulator of fracture healing and inhibits excessive bone regeneration by producing multiple osteoblast inhibitors [83]. Osteolineage cells are considered to play a role in the establishment of the niche where B lymphopoiesis occurs, and abnormal osteoblastic function may result in the defect of B lymphopoiesis [84]. Some evidence has suggested that calvarial osteoblasts can support B-cell commitment and differentiation from hematopoietic stem cells (HSCs) [85]. It is noticeable that B cell infiltration is observed in alveolar bone loss induced by periodontitis, which is correlated with activation of RANKL pathway as well as low levels of memory B cells [86, 87]. However, the effect of interaction between B cells and osteoclasts on tooth movement is still illegible. In-depth research should be conducted.

Like osteoclast, osteoblast is also the target of immune-associated hormones. Glucocorticoids inhibit osteoblastogenesis and promote apoptosis of osteoblasts, thus causing osteoporosis during its long-term use [88]. Parathyroid hormone acts directly on osteoblast and stimulates its differentiation and formation via STAT3/β-catenin during OTM [89–91]. Li et al. also observed upregulated osteogenic proteins OC, ALP, and IGF-1 in the gingival cervical fluid of mice after intermittent parathyroid hormone treatment [92]. There is substantial evidence to support the effect of estrogen deficient on bone mass and bone microarchitecture [93–95]. This is because estrogen deficient destroys directly bone forming induced by osteoblast, though this effect is milder than activation of osteoclast. Another possible reason

![Figure 2: Sources of osteoclasts in alveolar bone. Osteoclast can be derived from myeloid progenitor, mpeg1-positive macrophages, and dendritic cells. Meanwhile, it can be recruited by γδ T cell as well.](image)
can be increased inflammatory cytokines levels in the postmenopausal patients (e.g., TNFα, IL-1β, and IL-6), which have impact on bone homeostasis [93]. In brief, the interaction between hormone and osteocyte should be considered during orthodontic treatment of patients with special hormonal status.

3. External Root Resorption

Alveolar bone remodels under compression while tooth root is protected by cementum from the force [96]. Discrepancy in their response is considered the biological basis of orthodontic tooth movement. Nevertheless, destruction of root, termed the external root resorption (ERR), can still occur on mineralized cementum or dentine due to the presence of osteoclast-like multi, or occasionally mononucleated cells, called odontoclasts [97]. External root resorption occurring during orthodontic treatment has been confirmed as an iatrogenic disorder due to sterile inflammation [98, 99]. Histological root resorption is detected in over 90% orthodontically treated teeth, and the incidence of root resorption below 2 mm ranges from 48% to 66% [100, 101]. This non-infective, slight resorption is known as external surface resorption (ESR) which can only be confirmed with radiographs. It stops once orthodontic pressure is removed. Teeth subjected ESR suggest blunted root apices and/or the shorter roots. Moreover, due to the repairment of cementum, this resorption is also considered self-limiting and localized [97, 102]. However, 5% orthodontic patients’ ERR can increase to more than 5 mm [103], which is the reaction to excessive orthodontic mechanical stimulus. Besides, the detailed mechanism remains unclear.

Osteoclasts and odontoclasts responsible for root resorption are significantly similar to each other. There are some parallels in their response to immune regulation. He et al. [16] suggested the induction of ERR by proinflammatory macrophage phenotype. Increased M1/M2 ratio upregulates the expressions of TNF-α, INF-γ, and nitric oxide, while anti-inflammatory cytokines, IL-10, and arginase I are inhibited in OTM. Enhanced inflammation leads to assemblage of odontoclasts/osteoblast and external root resorption in rats, which reveals that some immune cells that modulate macrophage polarization (e.g., helper T cells [104]) can have an effect on root resorption. NLRP3 inflammasome also positively regulates M1 macrophage to exaggerate root resorption through caspase-1/IL-1β signaling [19]. Furthermore, the biological reaction in OTM can involve systemic cellular recruitment since spleen reservoir monocytes are significantly reduced [105]. The regional inflammation and root resorption are attenuated by a systemic level of TNF-α inhibitor etanercept or IL-4 [16]. The above evidence suggests the correlation between regional complication of orthodontic and systemic immune system.

However, in contrast to conventional knowledge that inflammation always exacerbates ERR, the risk of root resorption is confirmed to be negatively correlated with classical proinflammatory cytokine IL-1β which stimulates osteoclast recruitment and alveolar resorption. P2X purinergic receptor 7 is a ligand-gated ion channel which binds to ATP and induce maturation and externalization of downstream IL-1β [106–108]. P2X7 knockout mice were found with more root resorption than wild-type under orthodontic force [109]. Al-Qawasmi et al. knocked out IL-1β in C57BL/6 mice and observed root resorption increased [110]. Besides, polymorphism at IL-1β genes (+3954) is correlated with production alteration of IL-1β, and people with lower IL-1β production genotype have higher risks to experience ERR [111]. The above studies support that IL-1β is negatively correlated with ERR and explains further why ERR shows clear genetic predisposition. Unfortunately, these reports failed to illuminate why deficient inflammation results in more severe ERR. Prevail theory suggests that deficiency of IL-1β inhibits alveolar remodeling, thus resulting in prolonged stress concentrated on the root of the tooth and the destruction of cementum [112, 113]. In other words, the critical initiator of ERR is mechanical stimulation, instead of inflammation. This theory is supported by some reports [114, 115] which observed decreased root resorption rate in animal model of bone loss. It is considered that lower bone density reduces stress in the PDL interface, thus decreasing ERR risk. However, there is controversy about linkage between bone density and root ERR. Though cone-beam CT imaging analysis suggests that lingual bone density is positively correlated with ERR, some clinical trials with a higher sample number achieved negative results [116, 117]. Sirisootorn [118] even reported that osteoporosis aggravated ERR in mice. Thus, it is necessary to conduct additional studies to further investigate involved mechanisms and explain the above contradictory conclusions.

Apart from IL-1β genes, other genetic variants that have been confirmed to be correlated with ERR predisposition include IRAK1, IL-17, IL-6, human vitamin D receptor (hVDR), and OPN genes. Many of them are also correlated with immune response [119–124]. In addition, ERR is also correlated with epigenetic machinery of some immune response-related genes [125]. Existing research has demonstrated that FOXP3 promoters in teeth experiencing ERR have higher levels of DNA methylation, which inhibits transcription factors from binding to their DNA binding sites, thus downregulate the expression of FOXP3. The suppression of FOXP3 genes has an impact on development of T3B2 show $132^{+}\text{?}>\text{regulatory T cells (Tregs)}$ [126, 127]. It is responsible for maintaining immune homeostasis by antagonizing effector T cells [128]. As more and more studies investigated the association between gene polymorphisms and the risk of EARR during orthodontic treatment, early diagnosis of risk patients is expected in the future.

Besides, some patients with special hormone status can face higher ESRR risk. Cementoblastic activities and the amount of new cementum formation are lower in ovariectomized rats, thus affecting the activation of extracellular signal-regulated kinase-1/2 pathway. Given the similarity between cementoblasts and osteoblasts, it is unsurprising that some scholars manage to reduce EARR by locally injecting a variety of bone forming associated hormones in animals (e.g., estrogen, thyroxine, prostaglandin E2, and parathyroid hormone) [129–132]. However, the underlying mechanisms and the effects of local application of hormones
on immune status remain unclear, and it is necessary to conduct further investigations.

4. Periodontal Response to Orthodontic Force Application

Existing research has suggested that periodontal soft tissue changes morphologically and functionally in orthodontic treatment [133]. Abnormalities of soft tissue which can be observed in OTM include gingivitis, gingival enlargement, gingival recession, and gingival invagination [134]. Adolescents tend to have higher chances of gingivitis and gingival enlargement compared with adults due to their unstable gonadal hormone level. Gingivitis, the most common soft tissue problem, has been considered to arise from the placement of full-mouth appliance which makes daily oral hygiene care routine more challenging. In fact, the correlation of orthodontic treatment and soft tissue is significantly more sophisticated. The increased retention of particles and dental plaque leads to significant changes of oral flora and salivary pH [135], thus contributing to periodontal diseases and carious lesions development [136, 137]. Naranjo et al.’s research reported increased in periodontal pathogen colonization, scores for bleeding on probing, plaque index, and gingival index after orthodontic bracket placement [138]. Moreover, elevations of the red complex species, P. gingivalis, and T. denticola in the subgingival biofilm [139], saliva, and the surfaces of brackets [140] have been detected at the early stage or in the middle-term of orthodontic treatment. Though the mean total counts of red complex fall back to baseline level or even lower 12 months after appliance placement [139]. Moreover, subgingival microflora disorder will result in host immune reaction changes. The gingival crevicular fluid (GCF) is the sample employed most frequently since it is easy to collect. GCF from patients with fixed appliance has been reported with a lower anti-inflammatory cytokine (IL-4) level and higher levels of proinflammatory cytokines (TNF-α, IL-1β, IL-8, and IL-6). IL-6 takes on a great significance in the prediction of GCF flow [137], and TNF-α, IL-1β, and IL-8 have positive correlation with bleeding on probing and probing depth [137, 141]. However, IL-4 is correlated with nonbleeding sites and no gingival overgrowth [141]. Besides, orthodontic appliance design is capable of modulating dynamic alteration in the oral microbial equilibrium. Removable appliance lowers plaque index and periodontal complications compared with conventional fixed appliance [142, 143]. Bergamo et al. [140] have demonstrated that the structure and material of bracket applied in orthodontic could also affect the level and adherence of bacterial species on it, although exact mechanisms remain ambiguous. Nevertheless, given the correlation of oral microorganisms with periodontal health status, cardiac problems, and immunosuppression [144–147], additional investigations are required to establish effective protocols that prevent periodontal disease, even systemic diseases, by improving orthodontic appliances.

Gingival enlargement is another complication that has been commonly identified in juvenile orthodontics patients with unstable gonadal hormone concentrations [148]. In general, it occurs 1-2 months after treatment [149]. In contrast to inflammatory enlargement showing deep red, soft, and easily bleeding lesions, orthodontic treatment-induced gingival overgrowth is thick, pink, and rarely bleeding [150]. Surlin et al. [151] found overgrowth upon hyperplasia of the basal lamina and hypertrophy of the intermediate layer, accompanied by less foamy acidophilic cytoplasm cells with the absence of chronic inflammatory infiltrate in the chorion. Mechanical irritation by orthodontic bands, chemical irritation by cements, food impaction, and less efficient oral hygiene maintenance has been confirmed as all etiologic factors for gingival enlargement [152]. However, some patients with good oral hygiene also undergo gingival overgrowth. In the above patients’ gingival sulcus, an increase in matrix metalloproteinases- (MMP-) 8 level is persisted [153], a collagenase involved in systemic inflammation, orthodontic pain, periodontitis, and persistent virus infection [153–157]. Nevertheless, there have been rare studies revealing the reasons that why orthodontic gingival enlargement patients are more sensitive to external stimulus compared with normal patients. Furthermore, as reported by some existing studies, nickel released from fixed appliance significantly affects gingival hyperplasia (Figure 3). Exposure of skin to nickel can cause allergic contact dermatitis (ACD) in susceptible subjects. In this delayed-type hypersensitivity (DTH) reaction, nickel penetrates the skin tissue and stimulates keratinocytes to secrete IL-1β and TNF-α which upregulate the major histocompatibility complex II (MHC II) molecule on antigen presenting cells (APCs) in skin, including Langerhans cells (LCs) and DCs. Besides, the above cytokines also regulate E-cadherin and chemokine secretion from APCs. Subsequently, nickel binds to MHC II molecule and is transferred with APCs to draining lymph node where naïve T cells accept happens [158–161]. Nickel would mostly result in immune activation of the Th1/Th17 and Th22 components [162]. In the nickel ion-induced gingival enlargement, keratinocytes are the most important targeted cells. Constant low-dose nickel induces autocrine activation of the keratinocytes to trigger proliferation [163], while increasing intercellular adhesion molecule 1 (ICAM1) expression on surface to facilitate lymphocyte adhesion [164, 165]. Activated keratinocytes release IL-1α to stimulate fibroblasts to secrete keratinocyte growth factors (KGF) binding to KGF receptors on keratinocytes to induce proliferation, and the receptor is also upregulated by nickel exposure [166]. Marchese et al. reported that when primary keratinocytes were cocultured with fibroblasts, their proliferative effects would be significantly enhanced [163]. As reported by Gursoy et al.’s research, no significant difference was found in nickel accumulation between samples with or without gingival overgrowth [150]. Thus, etiology of orthodontic-induced gingival enlargement can arise from MHC gene polymorphisms instead of nickel accumulation and nickel content of the fixed appliance. However, some researchers proposed a hypothesis that nickel can accumulate in epithelium rather than connective tissue to create a local high-dose environment. Yet, the above accumulation of nickel in epithelium has been only identified in three-dimensional in vitro model [167] and lacks support of
mechanistic studies. Another interesting theory is that nickel exposed via oral route can induce tolerance in nickel allergy as immune reaction of human gingival fibroblasts (HGF) is inconsistent with dermal fibroblasts in vitro [120]. In comparison with dermal fibroblasts, HGF suffering nickel exposure expresses lower levels of HIF-1α, vascular endothelial growth factor (VEGF), and chemotactic cytokines ligand 20 (CCL20). Besides, HGF activated by nickel via TLR4 expresses IL-10, instead of initiating an acute proinflammatory response as in dermal fibroblasts [168]. Another pathway of forming immune tolerance is dependent on B cell apoptosis, and nickel ions cause DNA strand breaks of B cell to induce splenic apoptosis. APCs capture the apoptotic bodies and cross-present their peptides to the regulatory T cells which is vital immune cells for systemic tolerance. In skin, keratinocyte suffering nickel exposure secretes higher levels of IL-1β and TNF-α which upregulate MHC II, E-cadherin, and chemokines in APCs. Those APCs present nickel by MHC II molecule to naïve T cells in lymph node to induce allergic contact dermatitis. Another two pathways of dermatitis include that nickel stimulates fibroblast to express HIF-1α, VEGF, and CCL20, and that nickel activates eTh1/Th17 and Th22 cells.

![Figure 3: The different effect of nickel ions on oral mucosa/gingiva and skin.](image)

(a) Keratinocyte. (b) Fibroblast. (c) B cell. (d) Treg. (e) T cell. (f) APC. (g) KGF receptor. (h) ICAM-1. (i) TLR4. (j) MHC II. In oral mucosa/gingiva, intercellular adhesion molecule 1 (ICAM1) on keratinocyte is elevated by nickel, which facilitates lymphocyte adhesion and chronic inflammation. Nickel ions also increase keratinocyte’s proliferation by autocrine pathway to cause gingival hyperplasia. An IL-1α/KGF/KGF receptor positive feedback loop is formed between keratinocyte and fibroblast to further stimulate proliferation. On the other hand, fibroblast is irritated to express anti-inflammatory cytokines IL-10 via TLR4, which dampens immune response. Another pathway of forming immune tolerance is dependent on B cell apoptosis, and nickel ions cause DNA strand breaks of B cell to induce splenic apoptosis. APCs capture the apoptotic bodies and cross-present their peptides to the regulatory T cells which is vital immune cells for systemic tolerance. In skin, keratinocyte suffering nickel exposure secretes higher levels of IL-1β and TNF-α which upregulate MHC II, E-cadherin, and chemokines in APCs. Those APCs present nickel by MHC II molecule to naïve T cells in lymph node to induce allergic contact dermatitis. Another two pathways of dermatitis include that nickel stimulates fibroblast to express HIF-1α, VEGF, and CCL20, and that nickel activates eTh1/Th17 and Th22 cells.

Furthermore, Invisalign aligner is a widely removable plastic orthodontic appliance. Since its constitution does not contain metal, Invisalign system is considered more biocompatible than traditional appliance. However, recent research has suggested that Invisalign aligners change cells behavior and regulate proinflammatory protein expression. This conclusion is consistent with the finding of Premaraj et al. [175]. Invisalign plastic eluent significantly decreases oral epithelial cell viability and barrier function. Interestingly, it also suggested that saliva can protect keratinocyte from eluate. However, the predominate cytotoxic ingredient of Invisalign remains ambiguous. Isocyanate, a component of Invisalign plastic, results in mucous membrane irritation, asthmatic, hypersensitivity reactions, and other health issues. When isocyanate contacts with oral tissues, it rapidly forms immunogenic hapten by binding to protein, thus leading to sensitization. It also leads to oral epithelial barrier disruption which magnifies the allergic reactions [176, 177]. Isocyanate induces an inflammatory reaction and nonspecific airway hyperresponsiveness, involving type 1 and type
2 immune responses [178]. It is observed that isocyanate-exposed animals have greater amounts of airway goblet cells, neutrophils, BAL eosinophils, CD4+ T-cells, and ILCs, with a predominant type 2 response [179, 180]. Thus, workplace exposure of isocyanate is associated with occupational asthma [181]. Besides, 3D resin must be used during the manufacturing process of aligner. The problem is that this 3D resin made of polymethyl methacrylate (PMMA) leaches out residual unpolymerized monomers with toxic effect [182]. Bisphenol A (BPA) is one of the monomers, which is widely known for its cytotoxicity and disruptive effect on endocrine [183]. It can also be detected in orthodontic adhesive [184]. However, it is controversial whether the amount of BPA in the saliva of orthodontic patients is sufficient to affect oral epithelial cells [184–186] since Invisalign plastic does not have the necessary ingredients to release bisphenol. Eliades et al. prepared eluent by immersing aligner for 2 months, and no estrogenic effects were detected [187]. In addition, some supplements may affect cells validity. Rogers et al. [188] reported light stabilizer Tinuvin 292 from dental resin for 3D printing released ovo-toxic leachates in vitro. In brief, it is suggested that although some orthodontic biomaterials may have adverse biological effects in vitro, there has not been any clinical trial offering solid evidence for cytotoxic of Invisalign aligner in patients’ oral environment.

5. Orthodontic Pain

Orthodontic pain is initiated by sterile inflammation following orthodontic force, involving vascular changes, cytokines release, and immune cells recruitment [189]. The pain arising from OTM lasts two to three days after appliance placement and tends to decrease by the fifth or sixth day [190]. The duration is dependent on inflammation development and endogenous analgesic mechanisms. What is more, innate immune system can play a part in modulating orthodontic pain as neuroimmune interactions in pain have been confirmed by a plenty of studies [30, 191–193]. Mast cells, neutrophils, macrophages, and T cells are capable of secreting mediators binding to receptors on peripheral nerve terminals to reduce threshold for nociceptor neurons to fire action potentials, i.e., sensitization [191]. In contrast, nociceptors release neuropeptides and neurotransmitters to modulate immune function by influencing immune cells. To be specific, histamine from mast cells stimulates peripheral terminals of nerves in a paracrine manner. Nociceptor neurons express several histamine receptors (including H1R, H2R, H3R, and H4R) correlated with pain sensitization [194]. Upon releasing, tryptase stored in secretory granules of mast cells can interact with protease activated receptor 2 (PAR-2) on nerve endings [195, 196]. The above process induces activation of the transient receptor potential cation channel subfamily V member 1 (TRPV1) channels to upregulate calcitonin gene related peptide (CGRP) and substance P (SP) from nerve terminals [197], thus initiating nociceptive transmission. Other cytokines involved in mater cell-nociceptor interaction consist of IL-5, 5-hydroxytryptamine (5-HT) and nerve growth factor (NGF) [198]. Activated nerve endings release neuropeptides to stimulate a vicious cycle of mast cells further amplifying vascular leakage [194]. Neutrophils and macrophages secrete leukotriene B4 (LTB4), TNF-β, IL-6, IL-1β, and prostaglandin to activate their receptors and downstream ion channels [191], so as to sensitize nociceptor neurons. Neuroimmune interaction is not limited to peripheral nerve ending. In the spinal cord dorsal horn, T cells and microglia, resident innate immune cell in the spinal cord and the brain, also interact with spinal cord to act on central neuronal sensitization, thus resulting in pain chronicity [199–201].

In OTM, compressed vessels contribute to local ischaemia, thus resulting in anaerobic respiration and local acidosis. The accumulated H+ binds to acid-sensing ion channel 3 (ASIC3) on periodontal nerve terminal to induce orthodontic pain [202, 203]. Since orthodontic pain sensation is transferred along axon to trigeminal ganglia, action potentials stimulate periodontal neuron endings for the release of CGRP and SP [189, 204–206]. The above neurogenic mediators upregulate prostaglandins that can modify orthodontic pain [207]. Since orthodontic pain is significantly common in treatment, pain management becomes a major concern for patients and clinicians. Application of NSAID inhibits the production of prostaglandin by reducing the activity of COX enzymes. As a result, orthodontic pain can be alleviated [208]. Opioids are capable of suppressing orthodontic pain by binding to midbrain periaqueductal gray (PAG), so it has been considered a vital site in ascending pain transmission and a major component of the descending pain inhibitory system [209–211]. However, the long-term application of opioids induces significant neuroinflammation since it can activate astrocytes and microglia by Toll-like receptor 4 (TLR4) in the central nervous system [212]. Morphine increases level of glial-derived proinflammatory cytokines, inhibiting expressions of GABA receptors and glutamate transporter proteins. As a result, outward potassium currents decrease, thus leading to an overall increase in excitability of nearby neurons [209, 212–214]. The neuroinflammation results in the reverse of morphine analgesia and the development of morphine tolerance [215], which can explain the reason why administration of lipopolysaccharide (LPS), a potent TLR4 agonist, decreases the analgesic efficacy of morphine [216]. Interestingly, electronic stimulation of dorsal PAG leads to decreased activity of peripheral blood natural killer (NK) cells [217]. Moreover, microinjection of morphine into the caudal aspect of the PAG brings about NK cell cytotoxicity to induce immune inhibition [218]. The mentioned findings reveal the immunoregulatory property of opioids and the role PAG plays.

However, orthodontic pain has been generally self-limited since acute inflammatory reaction is attenuated and tends to be chronic over time [219], and intrinsic analgesic mechanisms have also been found to play a role [220–222]. At the early stage of OTM, nerve fibers in PDL release neuropeptides which elicit a painful response [223, 224]. Nerve fibers containing neuropeptides in PDL of the rat first molar have been found to increase three days after force application and returned to normal after 14 days [225]. Furthermore, PAG has been reported as a critical neural circuit for endogenous opioid-mediated analgesia. The upregulation
of endogenous opioids and opioid receptors was identified on trigeminal nucleus during the orthodontic pain response [189, 226]. Orthodontic pain activates PAG to send analgesic signals only at late stages of each episode of orthodontic treatment [227, 228]. Considering the effect arising from pain on the patient compliance and risks for opioids abuse, the mechanisms of pain self-limitation should be clarified systematically, and novel analgesia methods should be explored to replace conventional pain relievers. Guo et al. [229] reported that systemic infusion of bone marrow stromal cells (BMSCs) can interact with monocytes/macrophages by producing chemokines CCL4 and CCR2 to relieve pain (antihyperalgesia) for months. It is therefore indicated that reducing orthodontic pain via the modulating immune system is recognized as a highly promising research direction.

6. Orthodontic Treatment for Diabetes Patients

Type 1 diabetes mellitus (T1DM) is an insulin-dependent syndrome due to autoimmune disease in juvenile [230]. Children with diabetes have higher risks for the development of periodontal disease. T1DM is capable of disrupting enamel and dentine formation, while accelerating tooth eruption [168–170] [231–233], which can influence orthodontic treatment. However, except for controlling blood-glucose before treatment, there is no systemic strategy for patients with T1DM. Besides, compared with type 2 diabetes mellitus (T2DM) that commonly occurs in elderly, pathogenesis of T1DM is characterized by autoimmune destruction of insulin-producing beta cells in the pancreas [234] and accompanied by insulin and increasing of serum proinflammatory cytokines level [235]. In theory, this immunoregulatory alteration influences orthodontic outcome, whereas there has been no solid evidence to support it, and its exact mechanisms remain unclear. There is research suggested that increased high-density lipoprotein (HDL) in T1DM may be detrimental to endothelial function [236]. It can increase permeability of periodontal capillary (HDL) in T1DM may be detrimental to endothelial function [236]. It can increase permeability of periodontal capillary and magnify inflammation reaction in orthodontic patients. The above theory is also indirectly supported by that higher expression of MMP 8 and 9 and accelerated tooth movement in diabetes rat model [237]. However, there has been no associated clinical data. Further investigations are expected to illuminate and eliminate adverse effects arising from diabetes-associated immune disorders on OTM.

7. Orthodontic Relapse

Existing research has suggested that orthodontic relapse is a common problem affecting the outcome of orthodontic treatment. It is hard to predict which patients are at risk of relapse and the extent of relapse in the long-term [238]. The cellular process of orthodontic relapse is similar to OTM. As teeth move in the alveolar bone, the periodontal ligament and gingivae remodel to the new position. Before they completely adjust, teeth can move along the direction of their original position due to the stretching of supra-alveolar gingival fibers, accompanied by osteoclast distribution shifting [238, 239]. Accordingly, it is unsurprising that NSAIDs is capable of reducing orthodontic distance relapse via regulating immune system in rats. Possible mechanisms comprise downregulating proinflammatory cytokines in PDL tissue, blocking CD4+ T-lymphocyte cells and TH1 cells significant for OTM in spleen, and inhibiting PGE2 to suppress osteoclast activation [5]. In addition, M2 macrophages play a critical role in the cessation of bone resorption and the initiation of tissue repair. Thus, abnormal M1/M2 ratio can lead to continuous bone resorption, and tooth movement even though orthodontic force is removed [16, 240]. In-depth investigations on the immune-alveolar bone interaction in relapse are required to foresee risk for relapse and find a novel method of relapse prevention to replace or assist conventional orthodontic retainer.

8. Conclusion

Immune system plays a certain role in OTM in numerous aspects. In this paper, factors correlated with immunomodulation are illustrated, and their possibility of acting as potential targets to improve orthodontic outcome or prevent complications is discussed.

**Abbreviations**

- 5-HT: 5-Hydroxytryptamine
- α-SMA: Alpha-smooth muscle actin
- ACD: Allergic contact dermatitis
- APCs: Antigen presenting cells
- ASIC3: Acid-sensing ion channel 3
- BMSCs: Bone marrow stromal cells
- BMPs: Bone morphogenetic proteins
- BPA: Bisphenol A
- C5: Complement component 5
- CCL20: Chemotactic cytokines ligand 20
- CGRP: Calcitonin gene related peptide
- DCs: Dendritic cells
- DTH: Delayed-type hypersensitivity
- ERR: External root resorption
- ESR: External surface resorption
- GC: Glucocorticoid
- GCF: Gingival crevicular fluid
- HDL: High-density lipoprotein
- HGF: Keratinocyte growth factors
- HIF-1: Hypoxia-inducible factor-1
- HSCs: Hematopoietic stem cells
- hVDR: Human vitamin D receptor
- ICAM-1: Intercellular adhesion molecule 1
- IGFs: Insulin-like growth factors
- IGF-1: Insulin-like growth factors
- KGF: Keratinocyte growth factors
- LCs: Langerhans cells
- LPS: Lipopolysaccharide
- LTB4: Leukotriene B4
- MAPK: Mitogen-activated protein kinase
- M-CSF: Macrophage colony-stimulating factor
- MHC II: Major histocompatibility complex II molecule
- MMP-8: Matrix metalloproteinases 8
- NF-κB: Nuclear factor-κB
NGF: Nerve growth factor  
NK cells: Natural killer cells  
OC: Osteocalcin  
OPN: Osteopontin  
OTM: Orthodontic tooth movement  
PAG: Periaqueductal gray  
PAR-2: Protease activated receptor 2  
PDLC: Periodontal ligament cell  
PDLSG: Periodontal ligament stem cells  
PGE₂: Prostaglandin E₂  
PMMA: Polymethyl methacrylate  
RANKL: Receptor activator of NF-κB ligand  
SP: Substance P  
TGF-β: Transforming growth factor-beta  
TLR4: Toll-like receptor 4  
TRPV1: Transient receptor potential cation channel subfamily V member 1  
VEGF: Vascular endothelial growth factor.

Data Availability

All data used during the study appear in the submitted article.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Y Gao wrote the alveolar bone remodeling and external root resorption parts and drew all figures. Qingqing M and Linxiang L wrote periodontal response part. Yangyang L and Xingjia L wrote orthodontic pain part. Wenjie X wrote diabetes and relapse parts. Xudong L and Hua W designed, revised, edited, and checked the information on the article. All authors read and approved the final manuscript.

References

[1] Y. Li, L. A. Jacox, S. H. Little, and C. C. Ko, “Orthodontic tooth movement: the biology and clinical implications,” The Kaohsiung Journal of Medical Sciences, vol. 34, no. 4, pp. 207–214, 2018.
[2] Y. Klein, O. Fleissig, D. Polak, Y. Barenholz, O. Mandelboim, and S. Chaushu, “Immunorthodontics: in vivo gene expression of orthodontic tooth movement,” Scientific Reports, vol. 10, no. 1, p. 8172, 2020.
[3] Y. Yan, F. Liu, X. Kou et al., “T cells are required for orthodontic tooth movement,” Journal of Dental Research, vol. 94, no. 10, pp. 1463–1470, 2015.
[4] L. Wu, Y. Su, F. Lin et al., “MicroRNA-21 promotes orthodontic tooth movement by modulating the RANKL/OPG balance in T cells,” Oral Diseases, vol. 26, no. 2, pp. 370–380, 2020.
[5] Y. Liu, T. Zhang, C. Zhang et al., “Aspirin blocks orthodontic relapse via inhibition of CD4(+) T lymphocytes,” Journal of Dental Research, vol. 96, no. 5, pp. 586–594, 2017.
[6] K. Okamoto, T. Nakashima, M. Shinohara et al., “Osteoimmunology: the conceptual framework unifying the immune and skeletal systems,” Physiological Reviews, vol. 97, no. 4, pp. 1295–1349, 2017.
[7] M. Tsukasaki and H. Takayanagi, “Osteoimmunology: evolving concepts in bone-immune interactions in health and disease,” Nature Reviews Immunology, vol. 19, no. 10, pp. 626–642, 2019.
[8] C. Jiang, Z. Li, H. Quan et al., “Osteoimmunology in orthodontic tooth movement,” Oral Diseases, vol. 21, no. 6, pp. 694–704, 2015.
[9] J. Liu, J. Ruan, M. D. Weir et al., “Periodontal bone-ligament-cementum regeneration via scaffolds and stem cells,” Cell, vol. 8, no. 6, 2019.
[10] K. Noda, Y. Nakamura, K. Kogure, and Y. Nomura, “Morphological changes in the rat periodontal ligament and its vascularity after experimental tooth movement using superelastic forces,” The European Journal of Orthodontics, vol. 31, no. 1, pp. 37–45, 2009.
[11] B. F. Boyce, “Advances in the regulation of osteoclasts and osteoclast functions,” Journal of Dental Research, vol. 92, no. 10, pp. 860–867, 2013.
[12] D. Yang and Y. Wan, “Molecular determinants for the polarization of macrophage and osteoclast,” Seminars in Immunopathology, vol. 41, no. 5, pp. 551–563, 2019.
[13] J. Lassus, J. Salo, W. A. Jiranek et al., “Macrophage activation results in bone resorption,” Clinical Orthopaedics and Related Research, vol. 352, 1998.
[14] J. Muñoz, N. S. Akhavan, A. P. Mullins, and B. H. Arjmandi, “Macrophage polarization and osteoporosis: a review,” Nutrients, vol. 12, no. 10, 2020.
[15] D. He, F. Liu, S. Cui et al., “Mechanical load-induced H2S production by periodontal ligament stem cells activates M1 macrophages to promote bone remodeling and tooth movement via STAT1,” Stem Cell Research & Therapy, vol. 11, no. 1, p. 112, 2020.
[16] D. He, X. Kou, Q. Luo et al., “Enhanced M1/M2 macrophage ratio promotes orthodontic root resorption,” Journal of Dental Research, vol. 94, no. 1, pp. 129–139, 2015.
[17] L. Chen, S. Mo, and Y. Hua, “Compressive force-induced autophagy in periodontal ligament cells downregulates osteoclastogenesis during tooth movement,” Journal of Periodontology, vol. 90, no. 10, pp. 1170–1181, 2019.
[18] V. O. Chami, L. Nunes, and J. Capelli Júnior, “Expression of cytokines in gingival crevicular fluid associated with tooth movement induced by aligners: a pilot study,” Dental Press Journal of Orthodontics, vol. 23, no. 5, pp. 41–46, 2018.
[19] J. Zhang, X. Liu, C. Wan et al., “NLRP3 inflammasome mediates M1 macrophage polarization and IL-1β production in inflammatory root resorption,” Journal of Clinical Periodontology, vol. 47, no. 4, pp. 451–460, 2020.
[20] N. Jiang, D. He, Y. Ma et al., “Force-induced autophagy in periodontal ligament stem cells modulates M1 macrophage polarization via AKT signaling,” Frontiers In Cell And Developmental Biology, vol. 9, article 666631, 2021.
orthodontic tooth movement,” Mediators of Inflammation, vol. 2020, Article ID 2814015, 2020.

[22] A. Marahleh, H. Kitaura, F. Ohori et al., “TNF-α directly enhances osteoclast RANKL expression and promotes osteoclast formation,” Frontiers in Immunology, vol. 10, p. 2925, 2019.

[23] H. Kitaura, A. Marahleh, F. Ohori et al., “Osteocyte-related cytokines regulate osteoclast formation and bone resorption,” International Journal of Molecular Sciences, vol. 21, no. 14, 2020.

[24] D. He, X. Kou, R. Yang et al., “M1-like macrophage polarization promotes orthodontic tooth movement,” Journal of Dental Research, vol. 94, no. 9, pp. 1286–1294, 2015.

[25] S. Zhang, H. Zhang, Z. Jin et al., “Fucoidan inhibits tooth movement by promoting restorative macrophage polarization through the STAT3 pathway,” Journal of Cellular Physiology, vol. 235, no. 9, pp. 5938–5950, 2020.

[26] A. Schröder, L. Barschkies, J. Jantsch et al., “Role of oxygen supply in macrophages in a model of simulated orthodontic tooth movement,” Mediators of Inflammation, vol. 2020, Article ID 5802435, 2020.

[27] M. K. Di, T. J. Kean, K. G. Bernardi et al., “Reduced bone loss in a murine model of postmenopausal osteoporosis lacking complement component 3,” Journal of Orthopaedic Research, vol. 36, no. 1, pp. 118–128, 2018.

[28] A. Ignatius, P. Schoengraf, L. Kreja et al., “Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β,” Journal of Cellular Biochemistry, vol. 112, no. 9, pp. 2594–2605, 2011.

[29] N. Jiang, W. Guo, M. Chen et al., “Periodontal ligament and alveolar bone in health and adaptation,” Tooth Movement, vol. 18, pp. 1–8, 2016.

[30] X. Chen, Z. Wang, N. Duan, G. Zhu, E. M. Schwarz, and C. Xie, “Osteoblast-osteoclast interactions,” Connective Tissue Research, vol. 59, no. 2, pp. 99–107, 2018.

[31] M. Yamaguchi, “RANK/RANKL/OPG during orthodontic tooth movement,” Orthodontics & Craniofacial Research, vol. 12, no. 2, pp. 113–119, 2009.

[32] H. Kanzaki, M. Chiba, K. Arai et al., “Local RANKL gene transfer to the periodontal tissue accelerates orthodontic tooth movement,” Gene Therapy, vol. 13, no. 8, pp. 678–685, 2006.

[33] H. Kanzaki, M. Chiba, I. Takahashi, N. Haruyama, M. Nishimura, and H. Mitani, “Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement,” Journal of Dental Research, vol. 83, no. 12, pp. 920–925, 2004.

[34] M. N. Weitzmann, “Bone and the immune system,” in Bone Toxicology, vol. 45, no. 7, pp. 363–398, Springer, 2017.

[35] Y. Li, M. Terauchi, T. Vikulin, S. Roser-Page, and M. N. Weitzmann, “B cell production of both OPG and RANKL is significantly increased in aged mice,” The Open Bone Journal, vol. 6, pp. 8–17, 2014.

[36] M. Onal, J. Xiong, X. Chen et al., “Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss,” Journal of Biological Chemistry, vol. 287, no. 35, 2012.

[37] K. Titanji, I. Ofotokun, and M. N. Weitzmann, “Immature/transitional B-cell expansion is associated with bone loss in HIV-infected individuals with severe CD4+ T-cell lymphopenia,” AIDS (London, England), vol. 34, no. 10, pp. 1475–1483, 2020.

[38] Y. Li, G. Toraldo, A. Li et al., “B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo,” Blood, vol. 109, no. 9, pp. 3839–3848, 2007.

[39] S. Cenci, M. N. Weitzmann, C. Roggia et al., “Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha,” The Journal of Clinical Investigation, vol. 106, no. 10, pp. 1229–1237, 2000.

[40] E. Alspach, D. M. Lussier, and R. D. Schreiber, “Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity,” Perspectives in Biology, vol. 11, no. 3, 2019.

[41] A. Shapouri-Moghaddam, S. Mohammadian, H. Vazini et al., “Macrophage plasticity, polarization, and function in health and disease,” Journal of Cellular Physiology, vol. 233, no. 9, pp. 6425–6440, 2018.

[42] Y. Y. Kong, U. Feige, I. Sarosi et al., “Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand,” Nature, vol. 402, no. 6759, pp. 304–309, 1999.

[43] T. Kawai, T. Matsuymaya, Y. Hosokawa et al., “B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease,” The American Journal of Pathology, vol. 169, no. 3, pp. 987–998, 2006.

[44] R. Rizzoli and E. Biver, “Are probiotics the new calcium and vitamin D for bone health?,” Current Osteoporosis Reports, vol. 18, no. 3, pp. 273–284, 2020.

[45] P. D’Amelio and F. Sassi, “Gut microbiota, immune system, and bone,” Calcified Tissue International, vol. 102, no. 4, pp. 415–425, 2018.

[46] J. D. Schepper, R. Irwin, J. Kang et al., “Probiotics in gut-bone signaling,” Understanding the Gut-Bone Signaling Axis, vol. 1033, pp. 225–247, 2017.

[47] M. Abboud and D. Papandreu, “Gut microbiome, probiotics and bone: an updated mini review,” Open Access Macedonian Journal Of Medical Sciences, vol. 7, no. 3, pp. 478–481, 2019.

[48] K. Sjögren, C. Engdahl, P. Henning et al., “The gut microbiota regulates bone mass in mice,” Journal of Bone and Mineral Research, vol. 27, no. 6, pp. 1357–1367, 2012.

[49] D. Verma, P. K. Garg, and A. K. Dubey, “Insights into the human oral microbiome,” Archives Of Microbiology, vol. 200, no. 4, pp. 525–540, 2018.

[50] R. D. Fouraux, M. R. Messora, L. F. de Oliveira et al., “Effects of probiotic therapy on metabolic and inflammatory parameters of rats with ligation-induced periodontitis associated with restraint stress,” Journal of Periodontology, vol. 85, no. 7, pp. 975–983, 2014.

[51] C. A. Pazzini, L. J. Pereira, T. A. da Silva et al., “Probiotic consumption decreases the number of osteoclasts during orthodontic movement in mice,” Archives of Oral Biology, vol. 79, pp. 30–34, 2017.

[52] I. Olejniczak, H. Oster, and D. W. Ray, “Glucocorticoid circadian rhythms in immune function,” Seminars In Immunopathology, vol. 44, no. 2, pp. 153–163, 2022.

[53] K. I. M. Hj, H. Zhao, H. Kitaura et al., “Glucocorticoids and the osteoclast,” Annals of the New York Academy of Sciences, vol. 1116, pp. 335–339, 2007.

[54] P. Kalinski, “Regulation of immune responses by prostaglandin E2,” The Journal of Immunology., vol. 188, no. 1, pp. 21–28, 2012.
[55] H. Kaji, T. Sugimoto, M. Kanatani, M. Fukase, M. Kume gawa, and K. Chihara, "Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase," *Journal of Bone and Mineral Research*, vol. 11, no. 1, pp. 62–71, 1996.

[56] C. Pilbeam, "Prostaglandins and bone," *Handbook of Experimental Pharmacology*, vol. 262, pp. 157–175, 2020.

[57] H. Kaji, T. Sugimoto, M. Kanatani, K. Nishiyama, and K. Chihara, "Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2," *Journal of Bone and Mineral Research*, vol. 12, no. 5, pp. 734–741, 1997.

[58] I. Take, Y. Kobayashi, Y. Yamamoto et al., "Prostaglandin E2 strongly inhibits human osteoclast formation," *Endocrinology*, vol. 146, no. 12, pp. 5204–5214, 2005.

[59] L. M. McNamara, "Osteocytes and estrogen deficiency," *Current Osteoporosis Reports*, vol. 19, no. 6, pp. 592–603, 2021.

[60] D. E. Hughes, A. Dai, J. C. Tiffée, H. H. Li, G. R. Mundy, and B. F. Boyce, "Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β," *Nature Medicine*, vol. 2, no. 10, pp. 1132–1136, 1996.

[61] W. Ling, K. Krager, K. K. Richardson et al., "Mitochondrial Sirt3 contributes to the bone loss caused by aging or estrogen deficiency," *IJC Insight*, vol. 6, no. 10, 2021.

[62] Z. Fan, H. Che, S. Yang, and C. Chen, "Estrogen and estrogen receptor signaling promotes allergic immune responses: effects on immune cells, cytokines, and inflammatory factors involved in allergy," *Allergologia et Immunopathologia*, vol. 47, no. 5, pp. 506–512, 2019.

[63] I. A. Uehara, L. R. Soldi, and M. J. B. Silva, "Current perspectives of osteoclastogenesis through estrogen modulated immune cell cytokines," *Life Sciences*, vol. 256, article 117921, 2020.

[64] B. C. Silva and J. P. Bilezikian, "Parathyroid hormone: anabolic and catabolic actions on the skeleton," *Current Opinion in Pharmacology*, vol. 22, pp. 41–50, 2015.

[65] E. Kerngard, N. K. Chawla, and K. Wesseling-Perry, "Gut microbiome, parathyroid hormone, and bone," *Current Opinion in Nephrology and Hypertension*, vol. 30, no. 4, pp. 418–423, 2021.

[66] T. Chen, Y. Wang, Z. Hao, Y. Hu, and J. Li, "Parathyroid hormone and its related peptides in bone metabolism," *Biochemical Pharmacology*, vol. 192, article 114669, 2021.

[67] W. J. Rody Jr., G. J. King, and G. Gu, "Osteoclast recruitment to sites of compression in orthodontic tooth movement," *American Journal of Orthodontics and Dentofacial Orthopedics*, vol. 120, no. 5, pp. 477–489, 2001.

[68] R. Xie, A. M. Kuijpers-Jagtman, and J. C. Maltha, "Osteoclast differentiation during experimental tooth movement by a short-term force application: an immunohistochemical study in rats," *Acta Odontologica Scandinavica*, vol. 66, no. 5, pp. 314–320, 2008.

[69] L. Wu, Z. Luo, Y. Liu et al., "Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATC1 activation," *Stem Cell Research & Therapy*, vol. 10, no. 1, p. 375, 2019.

[70] Q. T. Phan, W. H. Tan, R. Liu et al., "Cxcr9l and Cxcr3.2 regulate recruitment of osteoclast progenitors to bone matrix in a medaka osteoporosis model," *Proceedings of the National Academy of Sciences*, vol. 117, no. 32, pp. 19276–19286, 2020.

[71] S. Wald, A. Leibowitz, Y. Aizenbud et al., "γδ T cells are essential for orthodontic tooth movement," *Journal of Dental Research*, vol. 100, no. 7, pp. 731–738, 2021.

[72] G. E. Wise and G. J. King, "Mechanisms of tooth eruption and orthodontic tooth movement," *Journal of Dental Research*, vol. 87, no. 5, pp. 414–434, 2008.

[73] R. Holland, C. Bain, and A. Utreja, "Osteoblast differentiation during orthodontic tooth movement," *Orthodontics & Craniofacial Research*, vol. 22, no. 3, pp. 177–182, 2019.

[74] J. R. Arron and Y. Choi, "Bone versus immune system," *Nature*, vol. 408, no. 6812, pp. 535–536, 2000.

[75] J. M. Kim, C. Lin, Z. Stavre, M. B. Greenblatt, and J. H. Shim, "Osteoblast-osteoclast communication and bone homeostasis," *Cell*, vol. 9, p. 9, 2020.

[76] R. Baum and E. M. Graval lese, "Impact of inflammation on the osteoblast in rheumatic diseases," *Current Osteoporosis Reports*, vol. 12, no. 1, pp. 9–16, 2014.

[77] T. Hioki, H. Tokuda, G. Kuroyanagi et al., "Olive polyphenols attenuate TNF-α-stimulated M-CSF and II-6 synthesis in osteoblasts: Suppression of Akt and p44/p42 MAP kinase signaling pathways," *Biomedicine & Pharmacotherapy*, vol. 141, article 111816, 2021.

[78] F. J. Manzano-Moreno, V. J. Costela-Ruiz, L. Melguizo-Rodriguez et al., "Inhibition of VEGF gene expression in osteoblast cells by different NSAIDs," *Archives of Oral Biology*, vol. 92, pp. 75–78, 2018.

[79] W. Sorroseno, P. S. Bird, and G. J. Seymour, "Nitric oxide production by a human osteoblast cell line stimulated with Aggregatibacter actinomycetemcomitans lipopolysaccharide," *Oral Microbiology and Immunology*, vol. 24, no. 1, pp. 50–55, 2009.

[80] C. Saint-Pastou Terrier and P. Gasque, "Bone responses in health and infectious diseases: a focus on osteoblasts," *Journal of Infection*, vol. 75, no. 4, pp. 281–292, 2017.

[81] N. E. Hengartner, J. Fiedler, A. Ignatius, and R. E. Brenner, "IL-1β inhibits human osteoblast migration," *Molecular Medicine*, vol. 19, no. 1, pp. 36–42, 2013.

[82] K. Matsuoka, K. A. Park, M. Ito, K. Ikeda, and S. Takeshita, "Osteoclast-derived complement component 3a stimulates osteoblast differentiation," *Journal of Bone and Mineral Research*, vol. 29, no. 7, pp. 1522–1530, 2014.

[83] H. Zhang, R. Wang, G. Wang et al., "Single-cell RNA sequencing reveals B cells are important regulators in fracture healing," *Front Endocrinol (Lausanne)*, vol. 12, article 666140, 2021.

[84] L. Ding and S. J. Morrison, "Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches," *Nature*, vol. 495, no. 7440, pp. 231–235, 2013.

[85] J. Zhu, R. Garrett, Y. Jung et al., "Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells," *Blood*, vol. 109, no. 9, pp. 3706–3712, 2007.

[86] S. A. Hienz, S. Paliwal, and S. Ivanovski, "Mechanisms of bone resorption in periodontitis," *Journal of Immunology Research*, vol. 2015, Article ID 615846, 10 pages, 2015.

[87] C. M. Figueredo, R. Lira-Junior, and R. M. Love, "T and B cells in periodontal disease: new functions in a complex scenario," *International Journal of Molecular Sciences*, vol. 20, no. 16, 2019.

[88] P. Chotiyarnwong and E. V. McCloskey, "Pathogenesis of glucocorticoid-induced osteoporosis and options for
treatment," Nature Reviews Endocrinology, vol. 16, no. 8, pp. 437–447, 2020.

[89] H. Wu, Y. Xue, Y. Zhang, Y. Wang, and J. Hou, "PTH1-34 promotes osteoblast formation through Bclin1-dependent autophagic activation," Journal of Bone and Mineral Metabolism, vol. 39, no. 4, pp. 572–582, 2021.

[90] B. Arunugam, M. Vishal, S. Shrey et al., "Parathyroid hormone-stimulation of Runx2 during osteoblast differentiation via the regulation of lnC-SUPT3H-1:16 (RUNX2-AS1:32) and miR-6797-5p," Biochimie, vol. 158, pp. 43–52, 2019.

[91] C. Zhang, T. Li, C. Zhou et al., "Parathyroid hormone increases alveolar bone homoeostasis during orthodontic tooth movement in rats with periodontitis via crosstalk between STAT3 and β-catenin," International Journal of Oral Science, vol. 12, no. 1, p. 38, 2020.

[92] T. Li, Z. Yan, S. He et al., "Intermittent parathyroid hormone improves orthodontic retention via insulin-like growth factor-1," Oral Diseases, vol. 27, no. 2, pp. 290–300, 2021.

[93] V. Fischer and M. Haffner-Luntzer, "Interaction between bone and immune cells: implications for postmenopausal osteoporosis," Seminars in Cell & Developmental Biology, vol. 123, pp. 14–21, 2022.

[94] D. Wu, A. Cline-Smith, E. Shashkova, A. Perla, A. Katyal, and R. Aurora, "T-cell mediated inflammation in postmenopausal osteoporosis," Frontiers in Immunology, vol. 12, article 687551, 2021.

[95] M. Notelovitz, "Estrogen therapy and osteoporosis: principles & practice," The American Journal of the Medical Sciences, vol. 313, no. 1, pp. 2–12, 1997.

[96] P. Rygh, "Orthodontic root resorption studied by electron microscopy," The Angle Orthodontist, vol. 47, no. 1, pp. 1–16, 1977.

[97] S. Patel and N. Saberi, "The ins and outs of root resorption," British Dental Journal, vol. 224, no. 9, pp. 691–699, 2018.

[98] R. Kunimatsu, A. Kimura, Y. Tsuka et al., "Baicalin inhibits root resorption during tooth movement in a rodent model," Archives of Oral Biology, vol. 116, article 104770, 2020.

[99] M. N. Gunraj, "Dental root resorption," Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, vol. 88, no. 6, pp. 647–653, 1999.

[100] M. Wishney, "Potential risks of orthodontic therapy: a critical review and conceptual framework," Australian Dental Journal, vol. 62, Supplement 1, pp. 86–96, 2017.

[101] M. R. Harry and M. R. Sims, "Root resorption in bicuspid intrusion. A scanning electron microscope study," The Angle Orthodontist, vol. 52, no. 3, pp. 235–258, 1982.

[102] J. O. Andreasen, "External root resorption: its implication in dental traumatology, paedodontics, periodontics, orthodontics and endodontics," International Endodontic Journal, vol. 18, no. 2, pp. 109–118, 1985.

[103] D. M. Killiany, "Root resorption caused by orthodontic treatment: An evidence-based review of literature," Seminars in Orthodontics, vol. 5, no. 2, pp. 128–133, 1999.

[104] L. C. Davies, S. J. Jenkins, J. E. Allen, and P. R. Taylor, "Tissue-resident macrophages," Nature Immunology, vol. 14, no. 10, pp. 986–995, 2013.

[105] M. Zeng, X. Kou, R. Yang et al., "Orthodontic force induces systemic inflammatory monocyte responses," Journal of Dental Research, vol. 94, no. 9, pp. 1295–1302, 2015.

[106] M. Barberà-Cremades, A. Baroja-Mazo, and P. Pelegrín, "Purinergic signaling during macrophage differentiation results in M2 alternative activated macrophages," Journal of Leukocyte Biology, vol. 99, no. 2, pp. 289–299, 2016.

[107] D. Ferrari, C. Pizzirani, E. Adinolfi et al., "The P2X7 receptor: a key player in IL-1 processing and release," The Journal of Immunology, vol. 176, no. 7, pp. 3877–3883, 2006.

[108] Y. Qu, L. Franchi, G. Nunez, and G. R. Dubyak, "Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages," The Journal of Immunology, vol. 179, no. 3, pp. 1913–1925, 2007.

[109] R. F. Viecilli, T. R. Katona, J. Chen, J. K. Hartsfield Jr., and W. E. Roberts, "Orthodontic mechanotransduction and the role of the P2X7 receptor," American Journal of Orthodontics and Dentofacial Orthopedics, vol. 135, no. 6, 2009.

[110] R. A. Al-Qawasmi, J. K. Hartsfield, E. T. Everett, M. R. Weaver, T. M. Foroud, and W. E. Roberts, "Root resorption associated with orthodontic force in IL-1Beta knockout mouse," Journal of Musculoskeletal and Neuronal Interactions, vol. 4, no. 4, pp. 383–385, 2004.

[111] R. A. Al-Qawasmi, J. K. Hartsfield Jr., E. T. Everett et al., "Genetic predisposition to external apical root resorption," American Journal of Orthodontics and Dentofacial Orthopedics, vol. 123, no. 3, pp. 242–252, 2003.

[112] A. Iglesias-Orte, L. A. Morford, and J. K. Hartsfield Jr., "Bone density and dental external apical root resorption," Current Osteoporosis Reports, vol. 14, no. 6, pp. 292–309, 2016.

[113] A. Ciurla, C. Marruganti, T. Doldo, and J. Szymanska, "Association between polymorphisms in the IL-1α, TNFRSF11B, CASP1, and IL-6 genes and orthodontic-induced external apical root resorption," Current Medicine, vol. 20, no. 18, 2021.

[114] R. S. Goldie and G. J. King, "Root resorption and tooth movement in orthodontically treated, calcium-deficient, and lactating rats," American Journal of Orthodontics, vol. 85, no. 5, pp. 424–430, 1984.

[115] M. Seifi, B. Ezzati, S. Saedi, and M. Hedayati, "The effect of ovariectomy and orchietomy on orthodontic tooth movement and root resorption in Wistar rats," Journal of Dentistry, vol. 16, no. 4, pp. 302–309, 2015.

[116] P. C. Scheibel, A. L. Ramos, L. C. Iwaki, and K. R. Micheletti, "Analysis of correlation between initial alveolar bone density and apical root resorption after 12 months of orthodontic treatment without extraction," Dental Press J Orthod, vol. 19, no. 5, pp. 97–102, 2014.

[117] L. L. Otis, J. S. Hong, and O. C. Tuncay, "Bone structure effect on root resorption," Dental Press Journal of Orthodontics, vol. 7, no. 3, pp. 165–177, 2004.

[118] I. Sirisoontorn, H. Hotokezaka, M. Hashimoto et al., "Tooth movement and root resorption; the effect of ovariectomy on orthodontic force application in rats," The Angle Orthodontist, vol. 81, no. 4, pp. 570–577, 2011.

[119] L. Y. Sharab, L. A. Morford, J. Dempsey et al., "Genetic and treatment-related risk factors associated with external apical root resorption (EARR) concurrent with orthodontia," Orthodontics & Craniofacial Research, vol. 18, Supplement 1, pp. 71–82, 2015.

[120] S. Pereira, L. Nogueira, F. Canova, M. Lopez, and H. C. Silva, "IRAK1 variant is protective for orthodontic-induced
external apical root resorption,” Oral Diseases, vol. 22, no. 7, pp. 658–664, 2016.

[112] Y. Guo, S. He, T. Gu, Y. Liu, and S. Chen, “Genetic and clinical risk factors of root resorption associated with orthodontic treatment,” American Journal of Orthodontics and Dentofacial Orthopedics, vol. 150, no. 2, pp. 283–289, 2016.

[113] P. Borilova Linhartova, P. Cernochova, J. Kastovsky, Z. Vrankova, M. Sirotkova, and L. Izaakovicova Holla, “Genetic determinants and postorthodontic external apical root resorption in Czech children,” Oral Diseases, vol. 23, no. 1, pp. 29–35, 2017.

[114] C. J. Chung, K. Soma, S. R. Rittling et al., “OPN deficiency suppresses appearance of odontoclastic cells and resorption of the tooth root induced by experimental force application,” Journal of Cellular Physiology, vol. 214, no. 3, pp. 614–620, 2008.

[115] M. L. Fontana, C. M. de Souza, J. F. Bernardino et al., “Association analysis of clinical aspects and vitamin D receptor gene polymorphism with external apical root resorption in orthodontic patients,” American Journal of Orthodontics and Dentofacial Orthopedics, vol. 142, no. 3, pp. 339–347, 2012.

[116] D. A. Barbato-Ferreira, S. F. Costa, R. S. Gomez, and J. V. Bastos, “DNA methylation patterns of immune response-related genes in inflammatory external root resorption,” Brazilian Oral Research, vol. 34, article e087, 2020.

[117] S. Horii, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription FactorFoxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003.

[118] E. Minskaia, B. C. Saraiva, M. M. Soares et al., “Molecular markers distinguishing T cell subtypes with TSDR strand-bias methylation,” Frontiers in Immunology, vol. 9, p. 2540, 2018.

[119] R. W. Kempkes, I. Joosten, H. J. Koenen, and X. He, “Metabolic pathways involved in regulatory T cell functionality,” Frontiers in Immunology, vol. 10, p. 2839, 2019.

[120] E. G. Kaklamanos, M. A. Makrygiannakis, and A. E. Athanasiou, “Does exogenous female sex hormone administration affect the rate of tooth movement and root resorption? A systematic review of animal studies,” PLoS One, vol. 16, no. 9, article e0257778, 2021.

[121] T. Li, H. Wang, C. Lv et al., “Intermittent parathyroid hormone promotes cementogenesis via ephrinB2–EPHB4 forward signaling,” Journal of Cellular Physiology, vol. 236, no. 3, pp. 2070–2086, 2021.

[122] Y. Hu, W. Liu, Z. Liu, W. Kuang, and H. He, “Receptor activator of nuclear factor-kappa ligand, OPG, and IGF-I expression during orthodontically induced inflammatory root resorption in the recombinant human growth hormone-treated rats,” The Angle Orthodontist, vol. 85, no. 4, pp. 562–569, 2015.

[123] E. Pourmros, E. Loberg, and C. Engström, “Thyroid function and root resorption,” The Angle Orthodontist, vol. 64, no. 5, pp. 389–393, 1994.

[124] L. Lo Russo, K. Zhurakivska, G. Montaruli et al., “Effects of crown movement on periodontal biotype: a digital analysis,” Odontology, vol. 106, no. 4, pp. 414–421, 2018.

[125] L. Zhao, X. Y. Wang, Y. Xu, and S. Meng, “Relationship of orthodontic treatment and periodontal soft tissue health,” Hua Xi Kou Qiang Yi Xue Za Zhi = West China Journal of Stomatology, vol. 36, no. 6, pp. 595–601, 2018.

[126] N. A. Meenan, “Iatrogenic possibilities of orthodontic treatment and modalities of prevention,” Journal of Orthodontic Science, vol. 2, no. 3, pp. 73–86, 2013.

[127] J. Gastel, M. Quirynen, W. Teughels, M. Pauwels, W. Coucke, and C. Carels, “Microbial adhesion on different bracket types in vitro,” The Angle Orthodontist, vol. 79, no. 5, pp. 915–921, 2009.

[128] J. van Gastel, M. Quirynen, W. Teughels, W. Coucke, and C. Carels, “Longitudinal changes in microbiology and clinical periodontal variables after placement of fixed orthodontic appliances,” Journal of Periodontology, vol. 79, no. 11, pp. 2078–2086, 2008.

[129] A. A. Naranjo, M. L. Triviño, A. Jaramillo, M. Betancourt, and J. E. Botero, “Changes in the subgingival microbiota and periodontal parameters before and 3 months after bracket placement,” American Journal of Orthodontics and Dentofacial Orthopedics, vol. 130, no. 3, p. 275.e17, 2006.

[130] M. U. Shirozaki, R. A. da Silva, F. L. Romano et al., “Clinical, microbiological, and immunological evaluation of patients in corrective orthodontic treatment,” Progress in Orthodontics, vol. 21, no. 1, p. 6, 2020.

[131] A. Z. Bergamo, P. Nelson-Filho, M. C. Andruccioli, C. do Nascimento, V. Pedrazzi, and M. A. Matsumoto, “Microbial complexes levels in conventional and self-ligating brackets,” Clinical Oral Investigations, vol. 21, no. 4, pp. 1037–1046, 2017.

[132] C. Giannopoulos, A. Mombelli, K. Tsinidou, V. Vasdekis, and J. Kamma, “Detection of gingival crevicular fluid cytokines in children and adolescents with and without fixed orthodontic appliances,” Acta Odontologica Scandinavica, vol. 66, no. 3, pp. 169–173, 2008.

[133] L. Levrini, A. Mangano, P. Montanari, S. Margherini, A. Caprioglio, and G. M. Abbate, “Periodontal health status in patients treated with the Invisalign(*) system and fixed orthodontic appliances: a 3 months clinical and microbiological evaluation,” European Journal Of Dentistry, vol. 9, no. 3, pp. 404–410, 2015.

[134] R. R. Miethke and K. Brauner, “A comparison of the periodontal health of patients during treatment with the Invisalign system and with fixed lingual appliances,” Journal of Orofacial Orthopedics/Fortschritte der Kieferorthopädie, vol. 68, no. 3, pp. 223–231, 2007.

[135] L. D. Gonçalves, S. M. Soares Ferreira, C. O. Souza, R. Souto, and A. P. Colombo, “Clinical and microbiological profiles of human immunodeficiency virus (HIV)-seropositive Brazilians undergoing highly active antiretroviral therapy and HIV-seronegative Brazilians with chronic periodontitis,” Journal of Periodontology, vol. 78, no. 1, pp. 87–96, 2007.

[136] A. C. Bresolin, M. M. Pronzatti, L. N. Pasqualotto et al., “Effectiveness of periodontal treatment on the improvement of inflammatory markers in children,” Archives of Oral Biology, vol. 59, no. 6, pp. 639–644, 2014.

[137] A. M. Valm, “The structure of dental plaque microbial communities in the transition from health to dental caries and periodontal disease,” Journal of Molecular Biology, vol. 431, no. 16, pp. 2957–2969, 2019.

[138] A. Mombelli, “Microbial colonization of the periodontal pocket and its significance for periodontal therapy,” Periodontology 2000, vol. 76, no. 1, pp. 85–96, 2018.

[139] H. A. Eid, H. A. Assiri, R. Kandyala, R. A. Toogoo, and V. S. Turakhia, “Gingival enlargement in different age groups
during fixed orthodontic treatment," *Journal of International Oral Health*, vol. 6, no. 1, pp. 1–4, 2014.

[149] B. U. Zachrisson and S. Zachrisson, "Gingival condition associated with partial orthodontic treatment," *Acta Odontologica Scandinavica*, vol. 30, no. 1, pp. 127–136, 1972.

[150] U. K. Gursoy, O. Sokucu, V. J. Uitto et al., "The role of nickel accumulation and epithelial cell proliferation in orthodontic treatment-induced gingival overgrowth," *The European Journal of Orthodontics*, vol. 29, no. 6, pp. 555–558, 2007.

[151] P. Surlin, A. M. Rauten, D. Pirici, B. Oprea, L. Mogoanta, I. Silosi, B. Oprea, and Ş. C. Marchese, V. Visco, L. Aimati et al., "Nickel-induced keratinocyte proliferation and up-modulation of the keratinocyte growth factor receptor expression," *Experimental Dermatology*, vol. 12, no. 4, pp. 497–505, 2003.

[164] M. C. Little and M. Neil, "The participation of proliferative keratinocytes in the preimmune response to sensitizing agents," *British Journal of Dermatology*, vol. 138, no. 1, pp. 45–56, 1998.

[165] M. Picardo, C. Zompertia, C. H. I. A. R. A. De Luca et al., "Nickel-keratinocyte interaction: a possible role in sensitization," *British Journal of Dermatology*, vol. 122, no. 6, pp. 729–735, 1990.

[166] N. Maas-Szabowska, A. Shimotoyodome, and N. E. Fusenig, "Keratinocyte growth regulation in fibroblast cocultures via a double paracrine mechanism," *Journal of Cell Science*, vol. 112, pp. 1843–1853, 1999.

[167] D. Trombetta, M. R. Mondello, F. Cimino, M. Cristani, S. Pergolizzi, and A. Saija, "Toxic effect of nickel in an in vitro model of human oral epithelium," *Toxicology Letters*, vol. 159, no. 3, pp. 219–225, 2005.

[168] L. Göz, E. Vestewig, M. Blankart et al., "Differences in human gingival and dermal fibroblasts may contribute to oral-induced tolerance against nickel," *Journal of Allergy and Clinical Immunology*, vol. 138, no. 4, pp. 1202–1205, 2016.

[169] M. Nowak, F. Kopp, K. Roelofs-Haarhuis, X. Wu, and E. Gleichmann, "Oral nickel tolerance: Fag ligand-expressing invariant NK T cells promote tolerance induction by eliciting apoptotic death of antigen-carrying, effect B cells," *Journal of Immunology*, vol. 176, no. 8, pp. 4581–4589, 2006.

[170] K. Danadevi, R. Rozati, B. S. Banu, and P. Grover, "In vivo genotoxic effect of nickel chloride in mice leukocytes using comet assay," *Food And Chemical Toxicology*, vol. 42, no. 5, pp. 751–757, 2004.

[171] K. Liu, T. Iyoda, M. Saternus, Y. Kimura, K. Inaba, and R. M. Steinman, "Immune tolerance after delivery of dying cells to dendritic cells in situ," *The Journal of Experimental Medicine*, vol. 196, no. 8, pp. 1091–1097, 2002.

[172] T. A. Ferguson, J. Herndon, B. Elzey, T. S. Grie, and N. Ishimaru, "Dermal and inhalation exposure to methylene bisphenyl isocyanate (MDI) in iron foundry workers," *Journal of International Oral Health*, vol. 54, no. 1, pp. 6–5, 2011.

[173] J. P. Allam, W. M. Peng, T. Appel et al., "Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells," *The Journal of Allergy and Clinical Immunology*, vol. 121, no. 2, pp. 368–374, 2008.

[174] J. P. Allam, Y. Duan, J. Winter et al., "Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites," *Allergy*, vol. 66, no. 4, pp. 532–539, 2011.

[175] T. Premaraj, S. Simet, M. Beatty, and S. Premaraj, "Functional involvement of E-cadherin in TGF-beta 1 induced cell cluster formation of in vitro developing human Langerhans-type dendritic cells," *The Journal of Experimental Medicine*, vol. 181, no. 6, pp. 2237–2247, 1995.

[176] E. Riedl, J. Stöckl, O. Majdic et al., "Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin," *The Journal of Experimental Medicine*, vol. 196, no. 4, pp. 417–430, 2002.

[177] G. Novak-Bilić, M. Vučić, I. Japundžić, M. Mstrovčić-Stefekov, S. Stanć-Duktač, and L. Lugović-Milić, "Irritant and allergic contact dermatitis - skin lesion characteristics," *Acta Clinica Croatica*, vol. 57, no. 4, pp. 713–720, 2018.

[178] C. Marchese, V. Visco, L. Aimati et al., "Nickel-induced keratinocyte proliferation and up-modulation of the keratinocyte growth factor receptor expression," *Experimental Dermatology*, vol. 12, no. 4, pp. 497–505, 2003.
A. Alhendi, R. Khounganian, A. Almudhi, and S. R. Ahamad, A. Halimi, H. Benyahia, L. Bahije, H. Adli, M. F. Azeroual, A. Sabour, M. El Helou, V. Roger-Leroi, and C. Bauer, E. Diamanti-Kandarakis, J. P. Bourguignon, L. C. Giudice

M. Ban, G. Morel, I. Langonné, N. Huguet, É. Pépin, and S. Binet, “TDI can induce respiratory allergy with Th2-dominated response in mice,” Toxicology, vol. 218, no. 1, pp. 39–47, 2006.

E. E. Blomme, S. Provoost, E. Bazzan et al., “Innate lymphoid cells in isocyanate-induced asthma: role of microRNA-155,” European Respiratory Journal, vol. 56, no. 3, 2020.

L. Svensson-Elfsmark, B. L. Koch, Å. Gustafsson, and E. E. Blomme, S. Provoost, E. Bazzan et al., H. Machelska and M. Celik, “Opioid receptors in immune and glial cells-implications for pain control,” Frontiers in Immunology, vol. 11, p. 300, 2020.
European Journal of Oral Sciences, vol. 127, no. 5, pp. 408–416, 2019.

[211] M. M. Bebehani, “Functional characteristics of the midbrain periaqueductal gray,” Progress in Neurobiology, vol. 46, no. 6, pp. 575–605, 1995.

[212] L. R. Watkins, M. R. Hutchinson, I. N. Johnston, and S. F. Maier, “Glia: novel counter-regulators of opioid analgesia,” Trends in Neurosciences, vol. 28, no. 12, pp. 661–669, 2005.

[213] X. Wang, L. C. Loram, K. Ramos et al., “Morphine activates neuroinflammation in a manner parallel to endotoxin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 16, pp. 6325–6330, 2012.

[214] M. R. Hutchinson, B. D. Coats, S. S. Lewis et al., “Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia,” Brain, Behavior, and Immunity, vol. 22, no. 8, pp. 1178–1189, 2008.

[215] J. A. DeLeo, F. Y. Tanga, and V. L. Tawfik, “Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia,” The Neuroscientist, vol. 10, no. 1, pp. 40–52, 2004.

[216] L. R. Watkins, M. R. Hutchinson, A. Ledeboer, J. Wieseler-J. A. DeLeo, F. Y. Tanga, and V. L. Tawfik, “Glia as the ‘bad guys’: Implications for improving clinical pain control and the clinical utility of opioids,” Brain, Behavior, and Immunity, vol. 21, no. 2, pp. 131–146, 2007.

[217] M. K. Demetriou, A. Siegel, J. S. Schleifer, J. Obedi, and S. E. Keller, “Electrical stimulation of the dorsal midbrain periaqueductal gray suppresses peripheral blood natural killer cell activity,” Brain, Behavior, and Immunity, vol. 8, no. 3, pp. 218–228, 1994.

[218] D. T. Lysle, K. E. Hoffman, and L. A. Dykstra, “Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status,” Journal of Pharmacology and Experimental Therapeutics, vol. 277, no. 3, pp. 1533–1540, 1996.

[219] P. Kapoor, O. P. Kharbanda, N. Monga, R. Miglani, and S. Kapila, “Effect of orthodontic forces on cytokine and receptor levels in gingival crevicular fluid: a systematic review,” Progress in Orthodontics, vol. 15, no. 1, pp. 65, 2014.

[220] A. Lesniak and A. W. Lipkowski, “Opioid peptides in peripheral pain control,” Acta Neurobiologiae Experimentalis, vol. 71, no. 1, pp. 129–138, 2011.

[221] W. G. Parris, F. S. Tanzer, G. H. Fridland, E. F. Harris, J. Killmar, and D. M. Desiderio, “Effects of orthodontic force on methionine enkephalin and substance P concentrations in human pulpal tissue,” American Journal of Orthodontics and Dentofacial Orthopedics, vol. 95, no. 6, pp. 479–489, 1989.

[222] J. A. Walker Jr., F. S. Tanzer, E. F. Harris, C. Wakelyn, and D. M. Desiderio, “The enkephalin response in human tooth pulp to orthodontic force,” American Journal of Orthodontics and Dentofacial Orthopedics, vol. 92, no. 1, pp. 9–16, 1987.

[223] V. Krishnan, “Orthodontic pain: from causes to management—a review,” The European Journal of Orthodontics, vol. 29, no. 2, pp. 170–179, 2007.

[224] V. Vandeveska-Radunovic, “Neural modulation of inflammatory reactions in dental tissues incident to orthodontic tooth movement. A review of the literature,” The European Journal of Orthodontics, vol. 21, no. 3, pp. 231–247, 1999.

[225] J. Kato, S. Wakisaka, and K. Kurisu, “Immunohistochemical changes in the distribution of nerve fibers in the periodontal ligament during an experimental tooth movement of the rat molar,” Cells, Tissues, Organs, vol. 157, no. 1, pp. 53–62, 2004.

[226] T. A. Balam, T. Yamashiro, L. Zheng, S. Murshid Ahmed, Y. Fujiyoshi, and T. Takano-Yamamoto, “Experimental tooth movement upregulates preproenkephalin mRNA in the rat trigeminal nucleus caudalis and oralis,” Brain Research, vol. 1036, no. 1–2, pp. 196–201, 2005.

[227] C. M. Magdalena, V. P. Navarro, D. M. Park, M. B. S. Stuani, and M. J. A. Rocha, “C-fos expression in rat brain nuclei following incisor tooth movement,” Journal of Dental Research, vol. 83, no. 1, pp. 50–54, 2004.

[228] M. H. Ossipov, G. O. Dussor, and F. Porreca, “Central modulation of pain,” The Journal of Clinical Investigation, vol. 120, no. 11, pp. 3779–3787, 2010.

[229] W. Guo, S. Imai, J. L. Yang et al., “In vivo immune interactions of multipotent stromal cells underlie their long-lasting pain-relieving effect,” Scientific Reports, vol. 7, no. 1, article 10107, 2017.

[230] C. Patterson, L. Guariguata, G. Dahlquist, G. Soltész, G. Ogle, and M. Silink, “Diabetes in the young - a global view and worldwide estimates of numbers of children with type 1 diabetes,” Diabetes Research and Clinical Practice, vol. 103, no. 2, pp. 161–175, 2014.

[231] H. Loe, “Periodontal disease. The sixth complication of diabetes mellitus,” Diabetes Care, vol. 16, no. 1, pp. 329–334, 1993.

[232] R. Orbak, S. Simsek, Z. Orbak, F. Kavrut, and M. Colak, “The influence of type-1 diabetes mellitus on dentition and oral health in children and adolescents,” Yonsei Medical Journal, vol. 49, no. 3, pp. 357–365, 2008.

[233] M. A. Abbassy, I. Watarí, A. S. Bakry et al., “Diabetes detrimental effects on enamel and dentine formation,” Journal of Dentistry, vol. 43, no. 5, pp. 589–596, 2015.

[234] K. M. Gillespie, “Type 1 diabetes: pathogenesis and prevention,” CMAJ, vol. 175, no. 2, pp. 165–170, 2006.

[235] T. Okdahl, C. Brock, T. Floréal et al., “Increased levels of inflammatory factors are associated with severity of polyneuropathy in type 1 diabetes,” Clinical Endocrinology, vol. 93, no. 4, pp. 419–428, 2020.

[236] S. T. Chiesa, M. Charakida, E. McLoughlin et al., “Elevated high-density lipoprotein in adolescents with Type 1 diabetes is associated with endothelial dysfunction in the presence of systemic inflammation,” European Journal Heart, vol. 40, no. 43, pp. 3559–3566, 2019.

[237] A. Vicente, L. A. Bravo-González, J. A. Navarro, A. J. Buendía, and F. Camacho-Alonso, “Effects of diabetes on oxidative stress, periodontal ligament fiber orientation, and matrix metalloproteinase 8 and 9 expressions during orthodontic tooth movement,” Clinical Oral Investigations, vol. 25, no. 3, pp. 1383–1394, 2021.

[238] S. J. Littlewood, S. Kandasamy, and G. Huang, “Retention and relapse in clinical practice,” Australian Dental Journal, vol. 62, Suppl 1, pp. 51–57, 2017.

[239] T. J. Franzen, P. Brudvik, and V. Vandeveska-Radunovic, “Periodontal tissue reaction during orthodontic relapse in rat molars,” European Journal of Orthodontics, vol. 35, no. 2, pp. 152–159, 2013.

[240] S. Chaushu, Y. Klein, O. Mandelboim, Y. Barenholz, and O. Fleissig, “Immune changes induced by orthodontic forces: a critical review,” Journal of Dental Research, vol. 101, no. 1, pp. 11–20, 2022.